A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

ClinicalTrials.gov ID: NCT07406360

Public ClinicalTrials.gov record NCT07406360. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Study identification

NCT ID: NCT07406360
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 1,209 participants

Conditions and interventions

Conditions

Interventions

MMRVNS Biological
MMRV Biological

Biological

Eligibility (public fields only)

Age range: 15 Months to 6 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 10, 2026
Primary completion: Feb 27, 2028
Completion: Jul 19, 2028
Last update posted: Jul 7, 2026

2026 – 2028

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
GSK Investigational Site	Birmingham	Alabama	35235	Recruiting
GSK Investigational Site	Walnut Creek	California	94598	Recruiting
GSK Investigational Site	Miami	Florida	33142	Recruiting
GSK Investigational Site	Miami	Florida	33182	Recruiting
GSK Investigational Site	Atlanta	Georgia	30310	Recruiting
GSK Investigational Site	Chicago	Illinois	60621	Recruiting
GSK Investigational Site	Farmington Hills	Michigan	48334	Recruiting
GSK Investigational Site	Dayton	Ohio	45406	Recruiting
GSK Investigational Site	Simpsonville	South Carolina	29680	Recruiting
GSK Investigational Site	Spartanburg	South Carolina	29301	Recruiting
GSK Investigational Site	Frisco	Texas	75033	Recruiting
GSK Investigational Site	Houston	Texas	77065	Recruiting
GSK Investigational Site	Houston	Texas	77077	Recruiting
GSK Investigational Site	Port Lavaca	Texas	77979	Recruiting
GSK Investigational Site	Richmond	Texas	77469	Recruiting
GSK Investigational Site	Provo	Utah	84604	Recruiting
GSK Investigational Site	Richmond	Virginia	23294	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07406360, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 7, 2026 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07406360 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →